Dan Lv
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Dan Lv has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Bo Lan
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
2 shared publications - Fei Ma
Department of Medical Oncology National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China
2 shared publications - Aipo Diao
College of Biotechnology, Tianjin University of Science and Technology, Tianjin, China
1 shared publication - Binghe Xu
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication - Bo-Chen Li
School of Science, Shenyang University of Technology, Shenyang 110870, China
1 shared publication Changyuan Guo
Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 25 February 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-14
Exploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer
Tumor heterogeneity and clonal evolution are related to the treatment resistance and disease progression in metastatic breast cancer (MBC). However, the process of clonal evolution and their relationship to prognosis remain unclear. This study aimed to elucidate the evolution of MBC through circulating tumor DNA (ctDNA) analysis and to develop a novel indicator for predicting treatment efficacy and prognosis. This multicenter retrospective study enrolled MBC patients who underwent next-generation sequencing between April 2016 and October 2022. The clonal evolution of tumors was inferred using PyClone and CITUP software. The study included 406 MBC patients. A cohort of 139 patients from the National Cancer Center served as the training cohort, while 267 patients from other centers comprised the validation cohort. In the training cohort, clonal analysis revealed that most MBCs exhibited branched clonal evolution, while a minority showed linear evolution. The branched evolution pattern was associated with slower disease progression (HR, 0.53; 95% CI, 0.32–0.87; P = 0.012). We introduced tumor clonal evolution rate (TER) as a novel concept to reflect the speed of clonal evolution. Survival analysis demonstrated that compared to the TER-high group, patients in the TER-low group had better progression-free survival (PFS) (HR, 0.62; 95% CI, 0.40–0.96; P = 0.033) and overall survival (OS) (HR, 0.45; 95% CI, 0.24–0.85; P = 0.013). Similarly, in the validation cohort, although the median OS was not reached, patients in the TER-low group had better prognosis compared to those in the TER-high group (HR, 0.41; 95% CI, 0.21–0.83; P < 0.001). Patients with branched evolution have better treatment efficacy than those with linear evolution. The TER shows potential as a biomarker for treatment efficacy and prognosis, providing new evidence that ctDNA is a valuable molecular indicator for predicting treatment outcomes in metastatic breast cancer.
- 25 February 2025
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-14
Open AccessExploration of the clonal evolution and construction of the tumor clonal evolution rate as a prognostic indicator in metastatic breast cancer
Tumor heterogeneity and clonal evolution are related to the treatment resistance and disease progression in metastatic breast cancer (MBC). However, the process of clonal evolution and their relationship to prognosis remain unclear. This study aimed to elucidate the evolution of MBC through circulating tumor DNA (ctDNA) analysis and to develop a novel indicator for predicting treatment efficacy and prognosis. This multicenter retrospective study enrolled MBC patients who underwent next-generation sequencing between April 2016 and October 2022. The clonal evolution of tumors was inferred using PyClone and CITUP software. The study included 406 MBC patients. A cohort of 139 patients from the National Cancer Center served as the training cohort, while 267 patients from other centers comprised the validation cohort. In the training cohort, clonal analysis revealed that most MBCs exhibited branched clonal evolution, while a minority showed linear evolution. The branched evolution pattern was associated with slower disease progression (HR, 0.53; 95% CI, 0.32–0.87; P = 0.012). We introduced tumor clonal evolution rate (TER) as a novel concept to reflect the speed of clonal evolution. Survival analysis demonstrated that compared to the TER-high group, patients in the TER-low group had better progression-free survival (PFS) (HR, 0.62; 95% CI, 0.40–0.96; P = 0.033) and overall survival (OS) (HR, 0.45; 95% CI, 0.24–0.85; P = 0.013). Similarly, in the validation cohort, although the median OS was not reached, patients in the TER-low group had better prognosis compared to those in the TER-high group (HR, 0.41; 95% CI, 0.21–0.83; P < 0.001). Patients with branched evolution have better treatment efficacy than those with linear evolution. The TER shows potential as a biomarker for treatment efficacy and prognosis, providing new evidence that ctDNA is a valuable molecular indicator for predicting treatment outcomes in metastatic breast cancer.
- Open Access
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
The characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study
Background: There is currently a lack of sufficient evidence on the prognosis of human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer (MIBC) and whether chemotherapy (CT) and targeted therapy can bring benefits. Objectives: To explore the prognosis and treatment of HER2-positive MIBC. Design: A retrospective multicenter study. Methods: In this multicenter real-world study, we consecutively enrolled patients who received local management and were diagnosed with lymph node-negative HER2-positive MIBC from January 2010 to December 2020. Results: A total of 163 patients were included. Thirty-nine patients (23.9%) received adjuvant CT, of which 12 patients (7.4%) received CT combined with trastuzumab. One patient received trastuzumab therapy alone. In total, nine patients (5.5%) experienced recurrence, and the 3-year disease-free survival (DFS) rate and 5-year DFS rate were both 95.1%. Kaplan–Meier analysis showed that patients aged ⩽40 had worse outcomes than those aged >40 (3-year DFS rate 81.8% vs 96.1%, p = 0.046). Using propensity score matching, we matched patients who received trastuzumab or CT ± trastuzumab with those who did not receive treatment based on age, tumor size, estrogen receptor status, and number of infiltration lesions. Patients who received targeted therapy or CT ± targeted therapy did not achieve further improvement in 3-year DFS rate (95.0% vs 95.0%, p = 0.630). Conclusion: HER2-positive MIBC has relatively good prognosis, and age ⩽40 years might be a poor prognostic factor. CT or targeted therapy seemed to bring little benefit for MIBC. Further prospective studies are needed to assess potential benefits of management for MIBC patients under the age of 40 years in the future.
- 1 January 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessThe characteristics of HER2-positive microinvasive breast cancer and the necessity of systemic adjuvant therapy in these patients: a multicenter real-world study
Background: There is currently a lack of sufficient evidence on the prognosis of human epidermal factor receptor 2 (HER2)-positive microinvasive breast cancer (MIBC) and whether chemotherapy (CT) and targeted therapy can bring benefits. Objectives: To explore the prognosis and treatment of HER2-positive MIBC. Design: A retrospective multicenter study. Methods: In this multicenter real-world study, we consecutively enrolled patients who received local management and were diagnosed with lymph node-negative HER2-positive MIBC from January 2010 to December 2020. Results: A total of 163 patients were included. Thirty-nine patients (23.9%) received adjuvant CT, of which 12 patients (7.4%) received CT combined with trastuzumab. One patient received trastuzumab therapy alone. In total, nine patients (5.5%) experienced recurrence, and the 3-year disease-free survival (DFS) rate and 5-year DFS rate were both 95.1%. Kaplan–Meier analysis showed that patients aged ⩽40 had worse outcomes than those aged >40 (3-year DFS rate 81.8% vs 96.1%, p = 0.046). Using propensity score matching, we matched patients who received trastuzumab or CT ± trastuzumab with those who did not receive treatment based on age, tumor size, estrogen receptor status, and number of infiltration lesions. Patients who received targeted therapy or CT ± targeted therapy did not achieve further improvement in 3-year DFS rate (95.0% vs 95.0%, p = 0.630). Conclusion: HER2-positive MIBC has relatively good prognosis, and age ⩽40 years might be a poor prognostic factor. CT or targeted therapy seemed to bring little benefit for MIBC. Further prospective studies are needed to assess potential benefits of management for MIBC patients under the age of 40 years in the future.
- 1 April 2023
- Published by IOP Publishing in Communications in Theoretical Physics
- Vol. 75 (4) , 045702
Compensation temperature and hysteresis behaviors of a graphene-like bilayer: Monte Carlo Study
Using the Monte Carlo method, the compensation temperature and hysteresis loops of a ferrimagnetic mixed spin-3/2 and spin-5/2 Ising-type graphene-like bilayer are investigated induced by different physical parameters such as crystal field, exchange coupling, external magnetic field, and temperature. The variations of magnetization, magnetic susceptibility, specific heat, and internal energy with the change of temperature are discussed. In addition, we also plot the phase diagrams including transition temperature and compensation temperature. Finally, multiple hysteresis loops under certain parameters are given.
- 1 April 2023
- Published by IOP Publishing in Communications in Theoretical Physics
- Vol. 75 (4) , 045702
Compensation temperature and hysteresis behaviors of a graphene-like bilayer: Monte Carlo Study
Using the Monte Carlo method, the compensation temperature and hysteresis loops of a ferrimagnetic mixed spin-3/2 and spin-5/2 Ising-type graphene-like bilayer are investigated induced by different physical parameters such as crystal field, exchange coupling, external magnetic field, and temperature. The variations of magnetization, magnetic susceptibility, specific heat, and internal energy with the change of temperature are discussed. In addition, we also plot the phase diagrams including transition temperature and compensation temperature. Finally, multiple hysteresis loops under certain parameters are given.
- 1 July 2016
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 76, 98-106
TMEPAI increases lysosome stability and promotes autophagy
- 1 July 2016
- Published by Elsevier in The International Journal of Biochemistry & Cell Biology
- Vol. 76, 98-106
TMEPAI increases lysosome stability and promotes autophagy